Cleared Traditional

K934775 - STC COCAINE METABOLITE EIA

K934775 is an FDA 510(k) clearance for STC COCAINE METABOLITE EIA, manufactured by Solarcare, Inc.. The device is a Class 2 Toxicology device with product code DIO cleared through the Traditional 510(k) pathway after a 647-day FDA review.

K934775 · Solarcare, Inc. · Toxicology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jul 1995
Decision
647d
Days
Class 2
Risk

K934775 is an FDA 510(k) clearance for the STC COCAINE METABOLITE EIA. Classified as Enzyme Immunoassay, Cocaine And Cocaine Metabolites (product code DIO), Class II - Special Controls.

Submitted by Solarcare, Inc. (Bethlehem, US). The FDA issued a Cleared decision on July 14, 1995 after a review of 647 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Toxicology FDA review panel, regulated under 21 CFR 862.3250 - the FDA toxicology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: High-complexity regulatory submission. Elevated predicate reliance profile. The extended review timeline suggests the FDA required additional documentation before confirming substantial equivalence - a pattern common in complex or first-of-kind Toxicology submissions.

View all Solarcare, Inc. devices

FDA 510(k) Submission Details - K934775

510(k) Number K934775 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received October 05, 1993
Decision Date July 14, 1995
Days to Decision 647 days
Submission Type Traditional
Review Panel Toxicology (TX)
Summary Statement
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
560d slower than avg
Panel avg: 87d · This submission: 647d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

DIO Device Classification - Class 2, Special Controls

Product Code DIO Enzyme Immunoassay, Cocaine And Cocaine Metabolites
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.3250
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Toxicology devices follow this clearance model.

Regulatory Peers - DIO Enzyme Immunoassay, Cocaine And Cocaine Metabolites

All 120
Devices cleared under the same product code (DIO) and FDA review panel - the closest regulatory comparables to K934775.
ABUSIGN(TM) DOA 4, DOA, THC/OPI/COC/AMP OR MET, BIOSIGN(TM) DOA 4, THC/OPI/COC/AMP OR MET
K945549 · Princeton BioMeditech Corp. · Oct 1995
ABUSIGN DOA 2, DOA, COC/THC, DOA2, BIOSIGN DOA2, COC/THC
K952361 · Princeton BioMeditech Corp. · Oct 1995
AXSYM COCAINE METABOLITE
K951289 · Abbott Laboratories · Aug 1995
VISUALINE II COCAINE
K950369 · Sun Biomedical Laboratories, Inc. · Mar 1995
EMIT IIC COCAINE METABOLITE ASSAY
K935323 · Syva Co. · Feb 1995
ABUSIGN(TM) COC, DOA-COC, ACCUSIGN(TM) COC, DOA-COC, DIOSIGN(TM) COC, DOA-COC
K945609 · Princeton BioMeditech Corp. · Feb 1995